. Suppaluek Na Songkla, Mr. Ittidet Phonin and Miss Nittaya Na Songkla offered company to buy SUTG stock for 132,000 units whereas 66% of total paid-up capital of SUTG. Main reason of the deal is to come back
the major shareholder of CSL. The acquisition deal in total was Bt3.4bn. Since Feb-18, AIS started to fully consolidate CSL’s revenue and cost accordingly. At present, the revenue from CSL is grouped
by full quarter TTTBB’s revenue recognition, offset by lack of large deal closed in 4Q23. SIM & Device sales reported Bt10,490mn,a 5.7% YoY increase, benefited from government tax incentive campaign
momentum in enterprise business, partially offset by reduced device sales revenue. Excluding TTTBB impact, total revenue increased 0.7% from lower device sales. Core service revenue (excluding IC and NT
subscribers increased 41% QoQ to stand at 5.5mn from efforts to encourage 5G adoption through affordable 5G packages and device bundling. AIS Fibre continued surging and closed 3Q22 at 2.1mn with net increase
subscribers increased 41% QoQ to stand at 5.5mn from efforts to encourage 5G adoption through affordable 5G packages and device bundling. AIS Fibre continued surging and closed 3Q22 at 2.1mn with net increase
subscribers increased 41% QoQ to stand at 5.5mn from efforts to encourage 5G adoption through affordable 5G packages and device bundling. AIS Fibre continued surging and closed 3Q22 at 2.1mn with net increase
business growth, while decreasing -0.5% QoQ from higher SG&A. EBITDA margin improved to 54% from continual focus in profitable revenue, cost management, and improved device margin. AIS reported a net profit
business growth, while decreasing -0.5% QoQ from higher SG&A. EBITDA margin improved to 54% from continual focus in profitable revenue, cost management, and improved device margin. AIS reported a net profit
enhanced device margin. AIS reported a net profit of Bt8,788mn, increasing 7.9% YoY reflecting strong operating performance, while increasing 2.5% QoQ from higher foreign exchange rate gain. 3Q24 MD&A